Biotech Funds: Enter With Care
Take the (FBIOX)Fidelity Select Biotechnology fund. It has the lowest expense ratio, 0.97%, of the 10 funds and a better performance for the year to date, last three years and past five years. The five-year return is a loss of 0.21%, but that's up against the average loss of 1.33%.
Manager Rajiv Kaul ran the Select Biotech during the late 1990s, when the fund exploded higher under his tenure. However, when he assumed control of two midcap growth funds, his performance was unimpressive. One fund badly trailed its peers, and another simply matched the performance of those in its category, according to Morningstar.
Kaul has decreased his exposure to some of the largest holdings in Select Biotech while spreading the wealth around to some smaller names such as Myogen (MYOG), which makes therapies for cardiovascular disease.
Despite the manager's track record in nonbiotech funds, Fidelity's offering is probably the best of the group because of its low cost and manager's experience.Unfortunately, the other decent funds have sky-high loads or minimum investments. (ETHSX)Eaton Vance Worldwide Health Science sports a 5.75% load and a 1.56% expense ratio, meaning you would need to be a long-term holder to make this one worth your while. Over the past five years, the fund has gained 3.06%. Only three out of eight funds with five-year track records have advanced over that time period. The Eaton Vance fund is 70% invested in biotech, and the rest is in pharmaceutical makers like Novartis (NVS) and Schering-Plough (SGP). The key to Eaton Vance's success is manager Sam Isaly, who heads Orbimed Advisors. Isaly has been investing in health care companies for nearly four decades. He runs hedge and private equity funds along with the Eaton Vance fund. While allocating his share of assets to the large-caps such as Amgen and Genentech, the manager prefers to invest in smaller names that may not even have products in the marketplace.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV